In this context, many other S1PR modulators have been developed to treat MS, aimed to produce compounds that selectively target only S1PR1 and S1PR5, the main effectors of fingolimod activity on immune and CNS cells. The gene discussed is S1PR1; the disease is myeloid sarcoma.